CMA Resurrects Claims Against Pfizer And Flynn On Phenytoin
UK Competition Regulator Once Again Alleges Pricing Abused Dominant Position
Executive Summary
After a court last year overturned CMA fines of almost £90m imposed on Pfizer and marketing partner Flynn Pharma over pricing for phenytoin sodium capsules, the UK competition regulator has issued a fresh statement of objections after reassessing the case in light of the ruling’s guidance on how unfair pricing should be evaluated.